Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
High-dose insulin therapy: is it time for U-500 insulin?
Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS. Lane WS, et al. Among authors: scism bacon jl. Endocr Pract. 2009 Jan-Feb;15(1):71-9. doi: 10.4158/EP.15.1.71. Endocr Pract. 2009. PMID: 19211405 Review.
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA. Buse JB, et al. Among authors: scism bacon jl. Diabetes Care. 2009 Jun;32(6):1007-13. doi: 10.2337/dc08-2117. Epub 2009 Mar 31. Diabetes Care. 2009. PMID: 19336625 Free PMC article. Clinical Trial.
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
Bergenstal RM, Garrison LP Jr, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH. Bergenstal RM, et al. Curr Med Res Opin. 2011 Mar;27(3):531-40. doi: 10.1185/03007995.2010.545814. Epub 2011 Jan 10. Curr Med Res Opin. 2011. PMID: 21219119